Sevion Therapeutics, Inc. (OTC: SVON) discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. Sevion’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multi-spanning membrane proteins and ion channels that play an important role in multiple diseases. For more information, visit the company’s website at www.seviontherapeutics.com.